Press Releases

Richard Kender Joins POXEL’s Board of Directors

Mar 12, 2015

Poxel Announces Positive Top Line Results for Its Antidiabetic Agent Imeglimin in a Phase 2b Dose-Ranging Trial

Dec 17, 2014

Poxel’s Anti-diabetic Imeglimin Confirms Its Unique Mechanism of Action in Type 2 Diabetic Patients

Oct 7, 2013

Poxel Appoints Khoso Baluch to its Board of Directors

Mar 21, 2013

First Patient In for Poxel’s Imeglimin Phase IIb Monotherapy Trial to Treat Type 2 Diabetes

Mar 7, 2013

Poxel Raises €13 million to Progress Imeglimin Development to Treat Type 2 diabetes

Dec 18, 2012

Poxel’s Anti-diabetic Imeglimin Shows Significant Clinical Benefits in Type 2 Diabetes when Added to Sitagliptin

Nov 5, 2012

New Clinical Results for an Anti-Diabetic Compound in Development at Poxel

Oct 26, 2011

Poxel Raises €16 million in a Series A Financing to Accelerate Pipeline Development

Jul 8, 2010

POXEL SAS Set-up to Find Innovative Solutions for Metabolic Diseases Management

Apr 22, 2009